Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 8, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512912) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512912 | approvedsource: Marketed | health-canada-dpd |
| Apr 7, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02504618) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02504618 | approvedsource: Marketed | health-canada-dpd |
| Apr 7, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02504596) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02504596 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 30, 2021 | Zanubrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BRUKINSA (DIN 02512963) under ATC L01EL03 ZANUBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02512963 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 25, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as HERZUMA (DIN 02506211) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02506211 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 25, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE FILM COATED TABLETS (DIN 02491400) under ATC L02BX03 ABIRATERONE. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 23, 2020 | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP GEFITINIB (DIN 02500663) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database… | DIN02500663 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 25, 2020 | Polatuzumab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as POLIVY (DIN 02499614) under ATC L01FX14 POLATUZUMAB VEDOTIN. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2020 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02464365) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 21, 2020 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02493551) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02493551 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 26, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-ABIRATERONE (DIN 02477114) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02477114 | approvedsource: Marketed | health-canada-dpd |
| Mar 24, 2021 | Decitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DEMYLOCAN (DIN 02484811) under ATC L01BC08 DECITABINE. Indications are not published in the Drug Product Database —… | DIN02484811 | approvedsource: Marketed | health-canada-dpd |
| Mar 19, 2021 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02504472) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02504472 | approvedsource: Marketed | health-canada-dpd |
| Mar 12, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02498111) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02498111 | withdrawnsource: Cancelled Post Marketsince Sep 25, 2025 | health-canada-dpd |
| Mar 10, 2021 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONUREG (DIN 02510200) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see… | DIN02510200 | approvedsource: Marketed | health-canada-dpd |
| Mar 10, 2021 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONUREG (DIN 02510197) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see… | DIN02510197 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499347) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499347 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499339) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499339 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499320) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499320 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499312) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499312 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499304) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499304 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499282) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499282 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509261) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509261 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509253) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509253 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02496860) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02496860 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02496852) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02496852 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 25, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-BENDAMUSTINE (DIN 02496895) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product… | DIN02496895 | approvedsource: Marketed | health-canada-dpd |
| Feb 25, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-BENDAMUSTINE (DIN 02496887) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product… | DIN02496887 | approvedsource: Marketed | health-canada-dpd |
| Feb 22, 2021 | Aminolevulinic Acid | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLEOLAN (DIN 02504928) under ATC L01XD04 AMINOLEVULINIC ACID. Indications are not published in the Drug Product… | DIN02504928 | approvedsource: Marketed | health-canada-dpd |
| Feb 22, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP ABIRATERONE (DIN 02502305) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02502305 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-ABIRATERONE (DIN 02503999) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02503999 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-ABIRATERONE (DIN 02503980) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02503980 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 25, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE FILM COATED TABLETS (DIN 02491397) under ATC L02BX03 ABIRATERONE. Indications are not published in… | DIN02491397 | approvedsource: Marketed | health-canada-dpd |
| Jan 25, 2021 | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-MELPHALAN (DIN 02480026) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database… | DIN02480026 | approvedsource: Marketed | health-canada-dpd |
| Jan 18, 2021 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NYVEPRIA (DIN 02506238) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02506238 | approvedsource: Marketed | health-canada-dpd |
| Jan 18, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ABIRATERONE (DIN 02494132) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02494132 | approvedsource: Marketed | health-canada-dpd |
| Jan 18, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ABIRATERONE (DIN 02486393) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02486393 | approvedsource: Marketed | health-canada-dpd |
| Jan 11, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ABIRATERONE (DIN 02501503) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02501503 | approvedsource: Marketed | health-canada-dpd |
| Jan 11, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ABIRATERONE (DIN 02492601) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02492601 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 23, 2020 | Sonidegib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ODOMZO (DIN 02500337) under ATC L01XJ02 SONIDEGIB. Indications are not published in the Drug Product Database — see… | DIN02500337 | approvedsource: Marketed | health-canada-dpd |
| Dec 10, 2020 | Ripretinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as QINLOCK (DIN 02500833) under ATC L01EX19 RIPRETINIB. Indications are not published in the Drug Product Database — see… | DIN02500833 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 24, 2020 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-IMATINIB (DIN 02490994) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02490994 | approvedsource: Marketed | health-canada-dpd |
| Nov 24, 2020 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-IMATINIB (DIN 02490986) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02490986 | approvedsource: Marketed | health-canada-dpd |
| Nov 13, 2020 | Larotrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VITRAKVI (DIN 02490323) under ATC L01EX12 LAROTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02490323 | approvedsource: Marketed | health-canada-dpd |
| Nov 13, 2020 | Larotrectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VITRAKVI (DIN 02490315) under ATC L01EX12 LAROTRECTINIB. Indications are not published in the Drug Product Database —… | DIN02490315 | approvedsource: Marketed | health-canada-dpd |
| Nov 11, 2020 | Decitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as INQOVI (DIN 02501600) under ATC L01BC58 DECITABINE, COMBINATIONS. Indications are not published in the Drug Product… | DIN02501600 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 8, 2020 | Tucatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TUKYSA (DIN 02499827) under ATC L01EH03 TUCATINIB. Indications are not published in the Drug Product Database — see… | DIN02499827 | approvedsource: Marketed | health-canada-dpd |
| Oct 5, 2020 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02494930) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02494930 | withdrawnsource: Cancelled Post Marketsince Jul 29, 2026 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 21, 2020 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02493543) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02493543 | approvedsource: Marketed | health-canada-dpd |
| Sep 21, 2020 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02493535) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02493535 | approvedsource: Marketed | health-canada-dpd |